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Summary
Background: As Chlamydia pneumoniae (Cp), a common cause of respiratory infection, is of vasotropic charac-
ter, chronic infection may be associated with the development of coronary disease, although
there have been few reports on the impact of Cp infection on the post-orthotopic heart trans-
plantation (OHT) survival rate.
Material/Methods: A total of 41 patients (4 females) were followed up for one year after OHT. Serology investiga-
tions for IgM, IgG and IgA antibodies against Cp were performed using the enzyme
immunoassay (EIA) method. Univariate and multivariate analyses were carried out with
respect to IgA, IgG, gender and type of cardiomyopathy. The IgA-IgG joint effect was also
studied.
Results: The one-year survival rate was reported for patients with IgA < 8 EIU to be 72.2%, whereas
those with IgA ≥ 8 EIU accounted for only 43.5% (Kaplan-Meier analysis, p = 0.0548). In
multivariate analysis IgA /IgG status proved to be a highly significant factor in survival. IgA
positive outcome combined with IgG negative outcome showed that the relative risk of death
equaled 12.08 versus other combinations of IgA/IgG status. In the Cox multivariate model
ischemic cardiomyopathy showed a relative risk of 2.79 (p=0.0594), although it was not signif-
icant in univariate analysis.
Conclusions: Chronic Cp infection, as expressed through a high IgA level, seems to have adverse impact on
the survival rate in one-year follow-up after OHT. IgA titers against Cp in heart transplant
recipients should therefore be assessed, as the high values might be a predictive risk factor
within the first post-operative year.
key words: Chlamydia pneumoniae infection • ischemic cardiomyopathy • orthotopic heart transplantation •
survival rate
Full-text PDF: http://www.MedSciMonit.com/pub/vol_9/no_2/3324.pdf
Word count: 2423
Tables: 1
Figures: 3
References: 35
Received: 2002.12.03
Accepted: 2002.12.06
Published: 2003.02.25
Author’s address: Piotr Pieniążek, MD, PhD, Department of Cardiac and Vascular Disease, Institute of Cardiology, Jagiellonian
University School of Medicine, ul. Prądnicka 80, 31-202 Kraków, Poland, email: kardio@kki.krakow.pl
Authors’ Contribution:
A Study Design
B Data Collection
C Statistical Analysis
D Data Interpretation
E Manuscript Preparation
F Literature Search
G Funds Collection
CR68
Med Sci Monit, 2003; 9(2): CR67-72Clinical Research
BACKGROUND
Infectious complications and early graft failure (EGF)
are widely believed to be one of the principal causes of
cardiac death after orthotopic heart transplantation
(OHT) within the peri-operative period [1,2]. Within
the first three months following surgery, infections are
the key morbidity factors, accounting for 75% of all
fatalities [1]. According to Kirsch et al. [1], morbidity
within the peri-operative period caused by various
infections accounts for 30% of all deaths. Similarly, a
high morbidity rate due to early graft failure has also
been observed within the same period, including unex-
plained acute early graft failure, pulmonary hyperten-
sion, right ventricle failure and hyperacute rejection.
In long-term OHT follow-up, such etiological factors as
opportunistic microbes of Toxoplasma gondi, Candida albi-
cans, Cytomegalovirus, Pneumocistis carini, or Herpes simplex
are reported to cause chronic infections [2]. Grattana et
al. [3] found that cytomegalovirus infection may effec-
tively exacerbate transplant rejection processes, as well
as accelerate atherosclerosis in the implanted heart.
Initial reports by Saikku et al. [4,5], later corroborated
by other authors [6,7,8], indicate that Chlamydia pneumo-
niae (Cp) infection may significantly accelerate the
progress of atherosclerosis and coronary artery disease.
Cp, an intracellular gram-negative bacterium, causes
infections of the respiratory system, frequently of chron-
ic and asymptomatic character. It may also invade the
circulatory system, causing inflammation in the arterial
walls, and by the same token exacerbating or accelerat-
ing atherosclerosis [9].
There have been to date very few reports dealing with
the incidence of Cp infections in transplant recipients
and its impact on prognosis in short- and long-term fol-
low-up after OHT. It is widely acknowledged that
ischemic cardiomyopathy is the most common reason
for referring patients with severe heart failure for OHT.
Chronic Cp infection is known to have a significant
bearing on the development of cardiac allograft vascu-
lopathy (CAV), which in due course accounts for much
worse long-term prognosis after heart transplantation
[10].
No studies have established to date whether there may
be any correlations between outcome and past, chronic
and acute Cp infections, as measured by anti-Cp IgG,
IgA and IgM antibodies in the transplant recipient dur-
ing OHT respectively, which could be of use as prog-
nostic factors in the postoperative follow-up. The pre-
sent study is therefore aimed at addressing this issue.
MATERIAL AND METHODS
The present study involved 41 consecutive patients
(including 4 females), mean age 50 years (range 28–68)
subjected to OHT in the period from July 1998 to
March 2000. The patients were referred for OHT on
the basis of comprehensive clinical investigations
(including coronary angiography, ventriculography,
right ventricle heart catheterization, and pulmonary
resistance, as well as endomyocardial biopsy). The biop-
sy, however, was not performed in patients diagnosed
with diffuse coronary atherosclerosis combined with
severe left ventricular impairment. In all the patients
included in the study, the peak oxygen consumption
was below 10 ml/kg/min, which has been shown to be
associated with the worst prognosis [11].
The patients subjected to OHT fell well within the crite-
ria for NYHA functional class IV, since they were diag-
nosed with progressive heart failure, despite having
been on multi-directional pharmacotherapy. Seventeen
patients were subjected to heart transplantation due to
idiopathic cardiomyopathy, whereas 24 patients were
qualified for surgery due to ischemic cardiomyopathy.
Immunosuppression treatment consisted of induction
therapy using anti-thymocyte globulin (ATG) adminis-
trated at a dose of 2.5 mg/kg/day, commencing immedi-
ately after surgery and continuing for 4–6 days.
Additionally, patients were treated with triple therapy
based on cyclosporin, azathioprin or mycophenolate
mofetil, and steroids.
Endomyocardial biopsy specimens were obtained with a
view to monitoring any possible graft rejection process
on routine protocol. Serological testing for Cp was car-
ried out within the first 24 hours of OHT.
In order to assess prior and current Chlamydia pneumoni-
ae infection serologically, IgG, IgA, and IgM levels in
the plasma of patients after heart transplantation were
determined using a single-point serology method.
Plasma was collected and stored at –26°C for up to two
weeks prior to the examination. The levels of IgG, IgA
and IgM antibodies were determined using commercial
EIA tests, in compliance with the manufacturer’s
instructions (Labsystem). The results were interpreted
in line with the criteria established by the manufacturer.
An increased IgG level (≥30 EIU) indicates past or cur-
rent Chlamydia infection. A persistent high level of IgG
antibodies encountered in an immunocompetent sub-
ject makes it possible to detect IgG even two years after
infection. Primary infection is characterized by an
increased level of IgM only. An increased IgM titer may
still be observed within 2–4 weeks after primary infec-
tion and is subsequently followed by IgG response. IgM
antibodies are usually undetectable 2–6 months after
primary infection.
An elevated or high IgG level, combined with persistent,
short-lived IgA, is considered to be a marker of chronic
Cp infection. In order to maintain consistency of inter-
pretation between EIA and the widely used microim-
munofluorescence methods, all samples equal to, or in
excess of, 8 EIU, were considered positive.
Statistical analysis 
Survival curves were estimated by Kaplan-Meier
method and then compared with the log-rank test.
Multivariate analysis was performed using a Cox model.
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The final model was obtained through the stepwise
regression approach. All the calculations were per-
formed on STATISTICA v. 6.0 software.
RESULTS
Out of the 41 patients after heart transplantation, 18
(43.9%) died within the first 360 days of the follow-up
period (the mean age of the deceased was 54 years,
whereas the mean age of the survivors was 48 years). Of
the 18 deceased, 7 (38.9%) died due to early graft fail-
ure, 5 (27.8%) due to multi-organ insufficiency, princi-
pally of cardio-pulmonary character, 4 (22.2%) due to
infections, and 2 (11.1%) as a result of transplant rejec-
tion process.
No increased level of IgM antibodies was encountered
in any of the 41 patients, which ruled out the possibility
of acute Cp infection at the time of OHT. Elevated titers
of IgG were encountered in 23 patients (56.1%), where-
as elevated IgA was also found in 23 patients (56.1%).
In our univariate analysis, the survival curves were com-
pared by the log-rank test. Only IgA positive outcome
(≥8) proved to be statistically significant at p=0.0548,
assuming a significance level at α=0.10 (Figure 1). The
other variables considered showed no significant impact
on the survival rate, including gender (p=0.9406), posi-
tive IgG (p=0.8577), cardiomyopathy (p=0.2558).
A detailed analysis led to the joint consideration of both
IgA and IgG levels. With four classes of positive/nega-
tive combinations, the differences in survival rate
proved to be highly significant at p=0.0040 (Figure 2).
For multivariate analysis, all the variables considered
were included in the initial Cox model. Then the final
model was obtained using a backwards stepwise proce-
dure (Figure 3).
It should be noted at this stage that all the patients with
positive IgA and negative IgG died within 6 months of
the surgery, whereas 1-year survival was noted in
patients with negative IgA and IgG, and was estimated
by the Kaplan-Meier method at 83.3%.
DISCUSSION
Serological evidence is a useful instrument for the
assessment of primary and chronic infections, both res-
piratory tract diseases [12] and cardiovascular diseases
[13,14]. Serological tests are commonly regarded as
inadequate in terms of facilitating localization of the
infection processes and likely current activity of the
pathogen. Culture-growing or PCR methods seem to be
far more efficient [15,16,17] in establishing elevated,
high-titered antibodies as markers of acute or chronic
chlamydial infection in large epidemiological studies
[4,5,18]. A review of laboratory methods for diagnosing
Cp infections indicates that the expanded gold standard
must include serology-based tests: microimmunofluo-
rescence (MIF) or enzyme immunoassay (EIA) [19].
In chronic chlamydial infections, IgA antibodies seem to
be a better marker than IgG antibodies, and are clearly
IgA/IgG status
Cardiomyopathy
IgA positive/
IgG negative
Other combinations
Idiopathic
Ischemic
6
35
17
24
12.08
1.00
1.00
2.79
0.0000
–
–
0.0594
Variable Value n Relativerisk p-value
Table 1. Cox proportional hazard model.
Figure 1. Kaplan-Meier survival curves related to IgA level.
Figure 2. Kaplan-Meier survival curves for IgA/IgG combinations.
Figure 3. Kaplan-Meier survival curves related to IgA positive/IgG neg-
ative versus other IgA/IgG combinations.
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indicative of a failed immunological response against an
intracellular bacterium. The prevalence of IgA antibod-
ies after an acute infection is relatively short, due to
their inherently shorter half-time, as opposed to IgG
antibodies, which tend to disappear much less rapidly.
Elevated and prolonged IgA titers are observed in
chronic bacterial infections, and are generally consid-
ered to be indicative of a chronic infection process [20].
The prospective studies published to date have revealed
that chronic Cp infection, as indicated by the incidence
of elevated IgA titer, is an independent risk factor for
the development of coronary heart disease [4,5] and
asymptomatic carotid atherosclerosis [18]. In the pre-
sent study, IgA level proved to be of better predictive
value for post-OHT mortality than IgG antibodies.
Several mechanisms of chronic chlamydial infection
account for the impact on OHT mortality. Cp may be
introduced into the human system through infected
peripheral blood monocytes [21], which are subsequent-
ly transformed into reservoirs for further infections. Cp
harbored in monocytes remains metabolically active and
participates in the maintenance of local immunological
response [22]. It has previously been demonstrated that
Cp has a direct impact on the activation of the proin-
flamatory and proliferative transcription factors, i.e. NF-
κB and AP-1, in human vascular smooth muscle cells
(VSMC) [23] and endothelium [24].
Chlamydial heat shock protein 60 (HSP60) induces
tumor necrosis factor (TNF-α) and matrix metallopro-
teinase (MMP) expression [23], and antibodies to
chlamydial HSP 60 mediate endothelial cytotoxicity
[25]. This finding suggests that bacteria act on the initial
defense mechanisms that mobilize humoral response to
eliminate the microorganisms. This mobilization may,
however, develop autoimmunological and inflammatory
processes, manifested as the systemic activation of
autoreactive T and B lymphocytes, followed by perivas-
cular fibrosis, fibrinous occlusions, and thickening of the
arterial walls [26].
In individuals with a failed immunodefense system (e.g.
HIV-1 infected children), the incidence of Cp infection
appears to correlate with the extent of immunosup-
pression [27]. In our population, pharmacologically
maintained immunosuppression may be an important
factor in desynchronizing humoral and cellular
response, usually stimulated by a bacterial infection. In
the case of Cp, which is an intracellular parasite, infec-
tion is usually of chronic character, and viable bacteria
may persist within the tissue, to be prospectively cul-
tured in vitro.
Immunosuppression facilitates the colonization of the
human system by Cp and disturbs the balance between
immunoresponse and cytotoxicity. In a vast majority of
cases, chronic infection induced by Cp, usually of
asymptomatic character, is hard to diagnose, and hence
the elevated levels of IgG and IgA antibodies, or the
presence of an ethiological factor within the system,
constitute the only markers [4,5]. Given the current
state of our knowledge in this respect, it would be rea-
sonable to conjecture that chronic Cp infection does in
fact have a profound impact on atherogenesis.
Our previous studies [28], conducted using DAKO anti-
bodies labeled against Cp and a confocal microscope,
attested to the presence of Cp bacteria in atherosclerotic
lesions in the arteries and aortic walls of transplant
recipients [29,30]; these findings have also been corrob-
orated by other authors [31].
Our preliminary results require further confirmation,
since the research was carried out on a relatively small
group of patients. Long-term prognosis in patients after
OHT may be influenced not only by the patient’s clini-
cal status, the professional expertise of the transplanting
surgeons, and the effectiveness of immunosuppression
therapy, but also by an adequate knowledge of Cp sta-
tus.
Of the 24 study patients with ischemic cardiomyopathy,
12 (50%) died, as compared to 6 (35%) of the 17
patients with idiopathic cardiomyopathy (p=0.0594).
This may have been due to chronic Cp infection, as the
survival curves encountered in patients with positive
IgA level seem to provide some grounds to prompt such
a conclusion.
It should be noted at this juncture that the vast majority
of deaths occurred within the first month after OHT,
i.e. within the most critical period. No correlation was
observed between the IgG level and the survival rate
after OHT. Of the relative handful of reports dealing
with this issue, only the article by Wittwer et al. [10] can
be cited at this point. The authors pointed out that posi-
tive level of IgA against Cp affected the development of
vasculopathy in the transplanted heart, which was not
the case, however, with respect to elevated IgG.
Despite rather limited data on this subject, it may rea-
sonably be assumed that the immunosuppressed state
would render chronic infection a plausible agent in the
etiology of CAV. Although chronic Cp infection may
adversely affect the long-term prognosis after OHT, this
hypothesis requires further research. In view of the
inherently shorter half-life of IgA, as compared to IgG
[32], monitoring is a matter of greater significance in
detecting chronic Cp infection. Post-operative immuno-
suppresion may activate the inflammatory process, as
observed by Fang et al. [33], who pointed out that the
prevalence of Cp antibodies in patients after OHT was
significantly higher (OR 13.7; 95%; CI 1.6 – 117.4), in
comparison to controls.
The findings of the present study pertain only to a small
number of patients, and so further research is required,
preferably using the PCR technique to assay for Cp-
DNA in leukocytes [30]. The acquisition of accurate data
on the level of Cp antibodies in patients referred for
OHT may well have potential for better long-term prog-
nosis. The results yielded by ISAR-3 [34] seem to lend a
certain plausibility to this hypothesis, as Roxithromycin
treatment perceptibly improved the outcome after PCI.
It may also be of some interest that Azithromycin treat-
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ment in animals has been found to retard atherogenesis
[35].
Although in the early post-operative period the thera-
peutic focus is predominantly on countering the trans-
plant rejection reaction, it may be of tangible benefit to
test for Cp infection. As evidenced by our research,
chronic Cp infection may adversely affect the patient
survival rate after OHT. Antibiotic treatment options
should therefore be seriously considered, especially in
patients with ischemic cardiomyopathy.
Admittedly, this issue is addressed only perfunctorily in
the literature on the subject matter, thus warranting
more complete investigations carried out on a much
larger population sample, preferably through random-
ized, double-blind studies focused specifically on antibi-
otic treatment.
The incidence of Cp infection in heart transplant recipi-
ents may be an additional risk factor within the first
year of OHT follow-up, especially with respect to
patients with ischemic cardiomyopathy.
Elevated IgA titer may attest to the incidence of chronic
Cp infection, accounting for perceptibly worse progno-
sis in patients after OHT. In the present study those
patients with negative IgA and IgG antibodies against
Cp showed a very high 1-year survival rate (83.3%).
More comprehensive investigations, however, should be
carried out on a much larger population sample in
order to extrapolate our present findings into a working
assumption of much wider implications.
CONCLUSIONS
Chronic Cp infection, as expressed by high IgA level,
seems to have an adverse impact on the survival rate
within one-year after OHT. IgA titers against Cp in
heart transplant recipients should therefore be assessed,
as high values may be a predictive risk factor within the
first post-operative year.
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